



Patient Information	Physician Information	Sample Information
Patient, Name Age/Sex: 81/M DOB: 07/11/1942 Phone#: 123-456-7890 Medical Rec#: 12345	Ordering Physician Name M.D. Client Name Address 1 Address 2 Phone : 123.456.7890 Fax : 123.456.7890	Accession#: UF24-01234 Date Collected: 03/25/2024 Date Received: 03/26/2024 Date Reported: 03/26/2024 Specimen: Voided Urine ICD 10: N39.0

Results: Positive

ORGANISM(S) - DETECTED

- Actinobaculum schaalii ≥100000 C FU/ml
- Klebsiella pneumoniae 10000-50000 C FU/ml
- Proteus mirabilis <10000 C FU/ml
- Viridans Group Streptococci**** ≥100000 C FU/ml

Report Key	Amoxicillin / Clavulanate	Cefaclor	Cephalexin	Levofloxacin	Sulfamethoxazole/Trimethoprim	Amikacin	Ceftriaxone	Gentamicin	Imipenem	Meropenem	Piperacillin / Tazobactam	Cefazolin	Cefepime	Cefoxitin	Ceftazidime / Avibactam	Fosfomycin	Vancomycin	Penicillin G	Ampicillin	Ciprofloxacin	Doxycycline	Nitrofurantoin
S = Sensitivity Detected R = Resistance Detected N = No Reference RGD = Resistance Gene(s) Detected	PO	PO	PO	PO/IV	PO/IV	IV/IM	IM/IV	IM/IV	IV	IV	IV	IV	IV	IV	IV	PO	IV	IV	PO/IV	PO/IV	PO/IV	PO
Sensitivity result:																						
Klebsiella pneumoniae	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	N	N	N	R	R	R	R
Proteus mirabilis	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S	N	N	N	S	S	R	R
Resistant Gene result :		RGD	RGD				RGD		RGD	RGD		RGD		RGD				RGD	RGD			
Organism(s) -Detected: + = Green Plus marks are supportive data and are NOT patient specific																						
Actinobaculum schaalii				+			+	+									+		+	+		+
Klebsiella pneumoniae	+			+	+	+	+	+	+	+	+	+	+	+	+					+		+
Proteus mirabilis	+	+		+		+	+	+		+	+	+	+	+	+				+	+		
Viridans Group Streptococci****	+	+	+	+			+		+	+	+	+	+	+	+		+					+

Information about the table:

Green Plusmarks + indicate there is supportive evidence that the antibiotic either FDA approved or off label can be used for treatment. Plusmarks treatment options are not intended to be prescriptive for any specific patient. Appropriate judgement should be exercised by the attending physician before prescribing a course of treatment. N = No reliable antibiotic reference is available for the detected organism. **If an organism is listed in the detected section but not reflected in the sensitivity result table, the organism is either fastidious or failed to grow in vitro and cannot be tested for antibiotic susceptibility.**

PHENOTYPIC SENSITIVITY DETECTED: Amikacin(IV/IM), Amoxicillin / Clavulanate(PO), Ampicillin(PO/IV), Cefaclor(PO), Cefazolin(IV), Cefepime(IV), Cefoxitin(IV), Ceftazidime / Avibactam(IV), Ceftriaxone(IM/IV), Cephalexin(PO), Ciprofloxacin(PO/IV), Gentamicin(IM/IV), Imipenem(IV), Levofloxacin(PO/IV), Meropenem(IV), Piperacillin / Tazobactam(IV), Sulfamethoxazole/Trimethoprim(PO/IV)

PHENOTYPIC RESISTANCE DETECTED: Ampicillin(PO/IV), Ciprofloxacin(PO/IV), Doxycycline(PO/IV), Nitrofurantoin(PO)

ANTIBIOTIC RESISTANCE GENES DETECTED: Extended-Spectrum-β-Lactamase*

ANTIBIOTIC RESISTANCE GENES NOT DETECTED: Carbapenem Resistance, Methicillin Resistance, Quinolone and Fluoroquinolone Resistance, Sulfonamides Resistance, Vancomycin Resistant (Glycopeptic antibiotics)

ORGANISM(S) - NOT DETECTED

• Testing performed at 524 E Elm St Conshohocken, PA 19428 | Medical Director: Joshua Cantor M.D.

Patient Name
Patient, Name

Accession Number
UF24-01234

Procedure Date
03/25/2024



Bacteria: Acinetobacter baumannii, Aerococcus urinae, Alloscardovia omnicolens, Citrobacter freundii, Citrobacter koseri, Coagulase negative Staphylococcus**, Corynebacterium riegelii, Enterobacter aerogenes***, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Klebsiella oxytoca, Morganella morganii, Mycoplasma hominis, Pantoea agglomerans, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Ureaplasma urealyticum

FUNGUS: Candida albicans, Candida auris, Candida glabrata, Candida parapsilosis

References:

* Extended Spectrum Beta-Lactamase (ESBL) Resistant genes identified confers resistance across multiple classes of antibiotics including Penicillin derivatives, cephalosporins, monobactams and carbapenems. Refer to the "Resistant Gene Detected" row to identify antibiotics for which the resistance gene may impact. Different ESBLs resistant genes will impact different beta lactam antibiotics in different levels and it is considered in the "Resistant Gene Detected" row.

** Coagulase Negative Staphylococcus includes Staphylococcus saprophyticus, Staphylococcus epidermidis, Staphylococcus haemolyticus.

*** Klebsiella aerogenes (formerly known as Enterobacter aerogenes)

**** Viridans Streptococci group includes Streptococcus anginosus, Streptococcus oralis and Streptococcus pasteurianus, Streptococcus mitis.

Disclaimer: This test was developed and its performance characteristics determined by laboratory. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approvals is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical testing. Urine specimens received greater than 5 days post collection may give unreliable cells/mL counts due to overgrowth of microorganism(s).

Methodology and Clinical Significance: Laboratory utilizes PCR amplification for the targeted detection of organisms. Pathogen ranges are "No Pathogenic DNA Detected", "<10,000", "10,000-50,000", "≥100,000" organism(s) per milliliter of sample. In addition, phenotypic susceptibility results are ascertained for the detected pathogen(s) by employing disk diffusion methods to obtain patient specific results. If an organism is listed in the detected section but not reflected in the sensitivity result table, the organism is either a fastidious organism or organism failed to grow in vitro and cannot be tested for antibiotic sensitivity. Note that antibiotic susceptibility testing is not performed for F-AST UTI orders per physician request.

Final Report signed by Signor on 03/26/2024 at 09:01 PM

• Testing performed at 524 E Elm St Conshohocken, PA 19428 | Medical Director: Joshua Cantor M.D.